Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952

Marijana Vujkovic, Aaron Kershenbaum, Lisa Wray, Thomas McWilliams, Shannon Cannon, Meenakshi Devidas, Linda Stork, Richard Aplenc

Research output: Contribution to journalArticle

2 Scopus citations


Genetic variation in drug detoxification pathways may influence outcomes in pediatric acute lymphoblastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961. Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI 1.2-8.6; rs2842947, OR 2.7, 95%CI 1.1-6.8; rs2842935, OR 2.5, 95%CI 1.1-5.0; rs10925235, OR 4.9, 95%CI 1.1-25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3-0.9). Our study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT, MTR and SLC19A1.

Original languageEnglish (US)
Pages (from-to)47-50
Number of pages4
JournalLeukemia Research Reports
Issue number2
Publication statusPublished - May 27 2015
Externally publishedYes



  • Acute lymphoblastic leukemia
  • Folate pathway
  • Relapse
  • SNPs

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this